FTC Clears Cephalon's $225M Gemin X Buyout
The Federal Trade Commission on Tuesday gave Cephalon Inc. the go-ahead for its $225 million acquisition of Gemin X Pharmaceuticals Inc., a privately held biopharmaceutical company developing cutting-edge cancer therapeutics....To view the full article, register now.
Already a subscriber? Click here to view full article